Gain Therapeutics (GANX) Receivables - Net (2020 - 2026)
Gain Therapeutics (GANX) posted quarterly Receivables - Net of $763606.0 for Q1 2026, up 19.51% year-over-year from $638961.0 in Q1 2025, and up 47.67% quarter-over-quarter from $517094.0 in Q3 2025.
Gain Therapeutics (GANX) Receivables - Net (2020 - 2026) Analysis & Trends
Gain Therapeutics' Receivables - Net history runs 5 years deep, the most recent figure standing at $763606.0 for Q1 2026.
- In Q1 2026, Receivables - Net rose 19.51% year-over-year to $763606.0; the TTM figure through Mar 2026 stood at $763606.0 (up 19.51% YoY), while the FY2025 annual figure was $622992.0, up 25.94% from the prior year.
- Receivables - Net for Q1 2026 stood at $763606.0, up from $517094.0 in the prior quarter.
- The five-year high for Receivables - Net was $1.1 million in Q2 2025, with the low at $494684.0 in Q4 2024.
- The 3-year median for Receivables - Net is $638961.0 (2025), against an average of $702145.6.
- Peak annual rise in Receivables - Net reached 19.51% in 2026, while the deepest fall reached 19.51% in 2026.
- Gain Therapeutics' Receivables - Net stood at $494684.0 in 2024, then climbed by 4.53% to $517094.0 in 2025, then soared by 47.67% to $763606.0 in 2026.
- Business Quant data shows GANX's Receivables - Net at $763606.0 in Q1 2026, $517094.0 in Q3 2025, and $1.1 million in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Gain Therapeutics | 85.12 Mn | 85.12 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 821,212.00 |
| Jun 30, 2026 | 821,212.00 |
| Mar 31, 2026 | 763,606.00 |
| Mar 31, 2026 | 763,606.00 |
| Sep 30, 2025 | 517,094.00 |
| Sep 30, 2025 | 517,094.00 |
| Jun 30, 2025 | 1.10 Mn |
| Jun 30, 2025 | 1.10 Mn |
| Mar 31, 2025 | 638,961.00 |
| Mar 31, 2025 | 638,961.00 |
| Dec 31, 2024 | 494,684.00 |
| Dec 31, 2024 | 494,684.00 |
| Sep 30, 2021 | 24,713.00 |
| Sep 30, 2021 | 24,713.00 |
| Jun 30, 2021 | 353,166.00 |
| Jun 30, 2021 | 353,166.00 |
| Mar 31, 2021 | 4,486.00 |
| Mar 31, 2021 | 4,486.00 |
| Dec 31, 2020 | 8,548.00 |
| Dec 31, 2020 | 8,548.00 |